FDA panel mixed on Dynavax hepatitis vaccine
Advisors to the US Food and Drug Administration have backed the efficacy of Dynavax' hepatitis B vaccine Heplisav but expressed concerns about its safety profile. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/fda_panel_mixed_on_dynavax_hepatitis_vaccine_976217